- Home
- CMMB vs PIII Comparison
CMMB vs PIII Comparison
Compare CMMB & PIII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- PIII
- Stock Information
- Founded
- CMMB 2004
- PIII 2015
- Country
- CMMB Israel
- PIII United States
- Employees
- CMMB N/A
- PIII N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- PIII Medical/Nursing Services
- Sector
- CMMB Health Care
- PIII Health Care
- Exchange
- CMMB Nasdaq
- PIII Nasdaq
- Market Cap
- CMMB 22.0M
- PIII 20.8M
- IPO Year
- CMMB N/A
- PIII N/A
- Fundamental
- Price
- CMMB $3.02
- PIII $8.53
- Analyst Decision
- CMMB Strong Buy
- PIII Strong Buy
- Analyst Count
- CMMB 2
- PIII 3
- Target Price
- CMMB $26.50
- PIII $17.50
- AVG Volume (30 Days)
- CMMB 108.4K
- PIII 6.9K
- Earning Date
- CMMB 08-14-2025
- PIII 08-14-2025
- Dividend Yield
- CMMB N/A
- PIII N/A
- EPS Growth
- CMMB N/A
- PIII N/A
- EPS
- CMMB N/A
- PIII N/A
- Revenue
- CMMB N/A
- PIII $1,461,823,000.00
- Revenue This Year
- CMMB N/A
- PIII N/A
- Revenue Next Year
- CMMB N/A
- PIII $9.46
- P/E Ratio
- CMMB N/A
- PIII N/A
- Revenue Growth
- CMMB N/A
- PIII 4.20
- 52 Week Low
- CMMB $3.02
- PIII $5.80
- 52 Week High
- CMMB $10.20
- PIII $29.19
- Technical
- Relative Strength Index (RSI)
- CMMB 19.63
- PIII 69.66
- Support Level
- CMMB $3.32
- PIII $8.08
- Resistance Level
- CMMB $3.86
- PIII $8.78
- Average True Range (ATR)
- CMMB 0.28
- PIII 0.48
- MACD
- CMMB -0.03
- PIII 0.14
- Stochastic Oscillator
- CMMB 2.65
- PIII 89.23
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
About PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.